Efficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta-analysis of randomized controlled trials.

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Basic & Clinical Pharmacology & Toxicology Pub Date : 2024-10-13 DOI:10.1111/bcpt.14092
Émilie Bortolussi-Courval, Connor Prosty, Jimin J Lee, Lisa M McCarthy, Emily G McDonald, Todd C Lee
{"title":"Efficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta-analysis of randomized controlled trials.","authors":"Émilie Bortolussi-Courval, Connor Prosty, Jimin J Lee, Lisa M McCarthy, Emily G McDonald, Todd C Lee","doi":"10.1111/bcpt.14092","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/rationale: </strong>Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.</p><p><strong>Objective: </strong>We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.</p><p><strong>Methods: </strong>We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (<30 ng/ml) comparing weekly versus daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum vitamin D levels.</p><p><strong>Findings: </strong>Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3-6.9, p = 0.6, favouring weekly dosing, I<sup>2</sup> = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3-2.1, p = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.</p><p><strong>Conclusions: </strong>Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bcpt.14092","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/rationale: Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.

Objective: We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.

Methods: We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (<30 ng/ml) comparing weekly versus daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum vitamin D levels.

Findings: Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3-6.9, p = 0.6, favouring weekly dosing, I2 = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3-2.1, p = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.

Conclusions: Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
每周与每天服用胆钙化醇补充血清维生素 D (25(OH)D) 缺乏症的疗效:随机对照试验的系统回顾和荟萃分析。
背景/原理:每周补充胆钙化醇可替代每日补充,以减轻用药方案复杂和维生素D缺乏症患者的药片负担,但支持这种转换的证据尚不明确:我们旨在确定每周补充胆钙化醇是否优于每天补充胆钙化醇,以补充维生素 D 缺乏症患者的营养:我们对涉及基线维生素 D 缺乏症患者的随机对照试验进行了系统回顾(结果:共纳入 8 项试验,涉及 542 名患者):八项涉及 542 名患者的试验被纳入分析。每周服用胆钙化醇和每天服用胆钙化醇在纠正维生素 D 过低方面没有显著差异(OR = 1.5,95% CI = 0.3-6.9,P = 0.6,倾向于每周服用,I2 = 85.3%)。一项排除其他健康患者的敏感性分析也得出了类似的结果(OR = 0.8,95% CI = 0.3-2.1,p = 0.6)。大多数研究存在偏倚风险;不同剂量的比较增加了异质性:有限的直接证据支持将胆钙化醇剂量从每天一次改为每周一次;但是,每周一次的补充并不会明显降低补充水平,而且还能减轻患者的日常用药负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.60
自引率
6.50%
发文量
126
审稿时长
1 months
期刊介绍: Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.
期刊最新文献
Diloxanide in amoebiasis management: Unravelling the mechanism of action and effectiveness. Long-term taurine supplementation regulates brain mitochondrial dynamics in mice. Syringin ameliorates dextran sulphate colitis via alteration oxidative stress, inflammation NF-κB signalling pathway and gut microbiota. Amount, type and storage of medicines in households - A survey for medicine users. sGC stimulator (BAY 41-8543) combined with PDE9 inhibitor (BAY 73-6691) reduces renal fibrosis in 5/6 nephrectomized rats.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1